By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gentronix today said that it has signed a three-year deal with GlaxoSmithKline, under which it will provide the drug maker with its GeneScreen HC and BlueScreen HC genotoxicity assays.

The Manchester, UK-based assay developer said that the agreement extends a pact with GSK for the GreenScreen HC to include the BlueScreen HC in 384-well format, which is its latest human cell reporter-based assay for compound profiling.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.